This HTML5 document contains 30 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n14https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbchttp://dbpedia.org/resource/Category:
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Antiestrogen_withdrawal_response
rdfs:label
Antiestrogen withdrawal response
rdfs:comment
The antiestrogen withdrawal response is a paradoxical improvement in breast cancer caused by discontinuation of antiestrogen therapy for breast cancer. It has been documented rarely with the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene. The phenomenon indicates that these agents can somehow result in stimulation of breast cancer tumor progression under certain circumstances. One proposed theory for the mechanism is that the sensitivity of breast cells to estrogens shifts with estrogen deprivation, and upon antiestrogen withdrawal, endogenous estrogen acts in the manner of high-dose estrogen therapy in the breast to inhibit breast cancer growth and induce breast cancer cell death. The antiestrogen withdrawal syndrome is analogous to but less common and well-known
dcterms:subject
dbc:Breast_cancer dbc:Antiestrogens
dbo:wikiPageID
64682792
dbo:wikiPageRevisionID
1040325995
dbo:wikiPageWikiLink
dbr:High-dose_estrogen dbr:Antiestrogen dbr:Antiandrogen dbr:Cell_death dbr:Endogenous dbr:Antiandrogen_withdrawal_syndrome dbr:Drug_discontinuation dbc:Antiestrogens dbc:Breast_cancer dbr:Tumor_progression dbr:Tamoxifen dbr:Raloxifene dbr:Tumor dbr:Breast_cancer dbr:Selective_estrogen_receptor_modulator dbr:Prostate_cancer
owl:sameAs
wikidata:Q97959683 n14:CvLfA
dbp:wikiPageUsesTemplate
dbt:Reflist dbt:Medicine-stub
dbo:abstract
The antiestrogen withdrawal response is a paradoxical improvement in breast cancer caused by discontinuation of antiestrogen therapy for breast cancer. It has been documented rarely with the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene. The phenomenon indicates that these agents can somehow result in stimulation of breast cancer tumor progression under certain circumstances. One proposed theory for the mechanism is that the sensitivity of breast cells to estrogens shifts with estrogen deprivation, and upon antiestrogen withdrawal, endogenous estrogen acts in the manner of high-dose estrogen therapy in the breast to inhibit breast cancer growth and induce breast cancer cell death. The antiestrogen withdrawal syndrome is analogous to but less common and well-known than the antiandrogen withdrawal syndrome, a phenomenon in which paradoxical improvement in prostate cancer occurs upon discontinuation of antiandrogen therapy.
prov:wasDerivedFrom
wikipedia-en:Antiestrogen_withdrawal_response?oldid=1040325995&ns=0
dbo:wikiPageLength
3110
foaf:isPrimaryTopicOf
wikipedia-en:Antiestrogen_withdrawal_response